Abstract
<jats:p>The problem of treating stable angina, as the most common clinical form of coronary artery disease and chronic coronary syndrome (CHS), lies in the difficulty of selecting a complex of antianginal drugs due to co-, polymorbidity, side effects, and the uncertainty of the root cause of the disease in a particular patient. All of the above makes it difficult to prescribe effective up stream therapy. Meanwhile, many of the above problems could be avoided by adding modern nutraceutical complexes recommended by relevant studies to the classic personalized therapy regimen. Among the most attractive, in our opinion, is the complex recently introduced to the pharmaceutical market of Ukraine, which includes: DHA 400mg + Policonasol 20mg) – “Cardionevrin Forte” [10]. The aim of the study was to analyze the effect of the new nutraceutical complex "Cardioneurin Forte" on cardiodynamics and lipid metabolism indicators and to develop recommendations for its inclusion in the treatment of CHD/CHD-stable angina with arterial hypertension and dyslipidemia. In this study, the therapeutic efficacy of the nutraceutical complex "Cardioneurin Forte" was compared with the control group by the dynamics of lipid spectrum indicators referring to data, obtained in the study of the nutraceutical complex "Cardioneurin" [17]. A total of 90 patients participated in the two studies. In the previous study (n = 60), the therapeutic efficacy and safety of the nutraceutical complex with a policosanol content of 10 mg was evaluated, while in the last study (n = 30) the efficacy of the new nutraceutical complex was studied, in which the dose of policosanol was doubled - to 20 mg. The nutraceutical complex "Cardioneurin Forte" enhances antianginal, antihypertensive properties and hemodynamic characteristics and effectively improves the dynamics of lipid metabolism in patients with coronary artery disease/chronic ischemic heart disease - stable angina. Conclusions. Strengthening of the antianginal and antihypertensive properties of standard drug pharmacotherapy with adding of the nutraceutical complex "Cardioneurin Forte" is characterized by increased physical activity, decreased shortness of breath, palpitations in comparison with the less pronounced dynamics of these clinical signs in the control group in the same direction, as well as more pronounced in the main group (standard treatment in combination with the studied nutraceutical complex) step-by-step antihypertensive therapy. Improvement of biomechanics of systolic and diastolic functions of the left ventricle according to Echocardiography and Speckle Tracking EchoCG data is more pronounced when adding the nutraceutical complex "Cardioneurin Forte" to the standard therapy of CHD/CHD-stable angina pectoris FC III. The lipid-lowering effect of the studied nutraceutical complex is not a replacement for pharmaceutical hypolipidemic drugs (statin therapy/bempedoic acid, ezetimibe, PCSK-9 inhibitors, inclisiran), but a significant addition to the standard treatment of CHD/CHD-stable angina pectoris with arterial hypertension and dyslipidemia. The positive effect of the recommended combination therapy is due to an increase in HDL-C levels, a decrease in non-HDL-C, LDL-C, and triacylglycerols in the presence of hypercholesterolemia and hypertriacylglycerolemia.</jats:p>